Skip to content
Glyburide
Diabeta, Glucovance, Glynase (glyburide) is a small molecule pharmaceutical. Glyburide was first approved as Micronase on 1984-05-01. It is used to treat type 2 diabetes mellitus in the USA. The pharmaceutical is active against ATP-sensitive inward rectifier potassium channel 11. In addition, it is known to target cystic fibrosis transmembrane conductance regulator, ATP-sensitive inward rectifier potassium channel 8, solute carrier organic anion transporter family member 2B1, and aldo-keto reductase family 1 member C1.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Diabeta, Glynase (generic drugs available since 1995-08-29, discontinued: Micronase)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glyburide
Tradename
Company
Number
Date
Products
GLYNASEMylanN-020051 RX1992-03-04
3 products, RLD
DIABETASanofiN-017532 RX1984-05-01
3 products, RLD, RS
Show 3 discontinued
Glyburide
+
Metformin hydrochloride
Tradename
Company
Number
Date
Products
GLUCOVANCEBristol Myers SquibbN-021178 DISCN2000-07-31
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
glucovanceNew Drug Application2012-04-23
glyburideANDA2023-06-20
glynaseNew Drug Application2017-10-07
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BB: Sulfonylureas for blood glucose lowering
— A10BB01: Glibenclamide
HCPCS
No data
Clinical
Clinical Trials
92 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E1133811631
Gestational diabetesD016640HP_0009800O24.42126313
Diabetes mellitusD003920EFO_0000400E08-E13—152210
Type 1 diabetes mellitusD003922EFO_0001359E10—11113
HypertensionD006973EFO_0000537I10———2—2
Vascular stiffnessD059289———112
Subarachnoid hemorrhageD013345EFO_0000713I60———2—2
ObesityD009765EFO_0001073E66.9———1—1
Blood pressureD001794EFO_0004325———1—1
CardiomegalyD006332EFO_0002503I51.7———1—1
Show 4 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PregnancyD011247EFO_0002950Z33.1——2—13
StrokeD020521EFO_0000712I63.9111——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Traumatic brain injuriesD000070642S0622———3
Ischemic strokeD00008324212———2
Brain neoplasmsD001932EFO_0003833C7111———1
Brain edemaD001929EFO_1000845G93.611———1
Drug-related side effects and adverse reactionsD064420T88.7—1———1
Transient neonatal hyperglycinemiaC562672—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—12———113
Angina pectorisD000787EFO_0003913I201————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HeadacheD006261HP_0002315R51————22
Cerebrovascular circulationD002560————11
Cerebral hemorrhageD002543————11
Reperfusion injuryD015427————11
Migraine disordersD008881EFO_0003821G43————11
PainD010146EFO_0003843R52————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameGLYBURIDE
INNglibenclamide
Description
Glyburide is an N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group. It has a role as a hypoglycemic agent, an anti-arrhythmia drug, an EC 2.7.1.33 (pantothenate kinase) inhibitor and an EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor. It is a N-sulfonylurea and a member of monochlorobenzenes.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
Identifiers
PDB4YVP
CAS-ID10238-21-8
RxCUI4815
ChEMBL IDCHEMBL472
ChEBI ID5441
PubChem CID3488
DrugBankDB01016
UNII IDSX6K58TVWC (ChemIDplus, GSRS)
Target
Agency Approved
KCNJ11
KCNJ11
Organism
Homo sapiens
Gene name
KCNJ11
Gene synonyms
NCBI Gene ID
3767
Protein name
ATP-sensitive inward rectifier potassium channel 11
Protein synonyms
beta-cell inward rectifier subunit, IKATP, Inward rectifier K(+) channel Kir6.2, inwardly rectifing potassium channel subfamily J member 11, inwardly rectifying potassium channel KIR6.2, inwardly-rectifying potassium channel subfamily J member 11, potassium channel inwardly rectifing subfamily J member 11, Potassium channel, inwardly rectifying subfamily J member 11, potassium voltage-gated channel subfamily J member 11
Uniprot ID
Q8IW96
Mouse ortholog
Kcnj11 (16514)
ATP-sensitive inward rectifier potassium channel 11 (Q9QX21)
Alternate
CFTR
CFTR
KCNJ8
KCNJ8
SLCO2B1
SLCO2B1
AKR1C1
AKR1C1
Organism
Homo sapiens
Gene name
CFTR
Gene synonyms
ABCC7
NCBI Gene ID
1080
Protein name
cystic fibrosis transmembrane conductance regulator
Protein synonyms
ATP-binding cassette sub-family C member 7, cAMP-dependent chloride channel, Channel conductance-controlling ATPase, cystic fibrosis transmembrane conductance regulating, cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7)
Uniprot ID
Q2I102
Mouse ortholog
Cftr (12638)
cystic fibrosis transmembrane conductance regulator (Q9JKQ6)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 16,744 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
425 adverse events reported
View more details